Lanthanum (La) deposition has been observed in gastrointestinal mucosa of dialysis patients treated with La carbonate to treat hyperphosphatemia in the 6 years since its authorization in Japan. We investigated gastrointestinal biopsies from 112 dialysis patients, and found 15 cases of histiocytic aggregation with crystalloids and one case of duodenitis with histiocyte aggregation without crystalloids in the 30 patients treated with La carbonate. No histiocytic lesions were observed in the 82 patients without La carbonate administration. So far in total 70 cases of La deposition in the alimentary tract have been reported, including our 16 cases. Neither clinical nor histological findings other than histiocytic aggregation were specific in the patients with La deposition. We also compared the groups with and without La deposition, revealing that the daily and total doses of La carbonate showed statistically significant correlations with La deposition. However the causality with their histologic features, e.g. intestinal metaplasia and degree of inflammation, were inconclusive between the two groups. Although no critical symptoms have been reported, it is necessary to accumulate more cases to clarify the mechanism of La deposition, because dialysis patients must take phosphate buffers for a long period.
There are several kinds of granulomatous gastritis: Crohn's disease, sarcoidosis, tuberculosis, and general foreign body reactions. In 2015, two reports 1,2 added a new type of histiocytic aggregation with lanthanum (La) deposition, which was analyzed by energy dispersive X-ray spectroscopy in dialysis patients treated with La carbonate (LaC, Fosrenol
1
). LaC is a relatively new phosphate binder with fewer side effects than previous medicines, and has been increasing in frequency of use. This medicine has been used for hyperphosphatemia of dialysis patients since 2005 in the United States and 2009 in Japan. In general phosphate binders bind to ingested phosphates to form insoluble complexes and are excreted unabsorbed in the feces. The tissue distribution of La has been investigated and demonstrated to be low tissue exposure due to effective tissue clearance mechanisms in the bone and liver. 3, 4 However, as the history of study of La deposition in the alimentary tracts is short, its developmental mechanism and effects are as yet unclear. For the last 3 years, we have experienced several cases with similar histiocytic aggregation in gastrointestinal biopsies and compared the clinical and pathological differences between the cases with and without histiocytic aggregations in 30 cases treated with LaC, and investigated their progress in some cases. We also reviewed their clinical backgrounds, along with pathological findings in literature cases.
MATERIALS AND METHODS
We selected cases of gastrointestinal endoscopic examinations of dialysis patients in Keijinkai Hospital from 2014 to 2016. All biopsy specimens, which were 10% formalin-fixed and paraffin-embedded, were stained with hematoxylin and eosin (HE staining). We also stained the biopsy specimens containing specific histiocytic aggregation including unknown crystals with direct fast scarlet (DFS), Prussian blue, Kossa and immunologically using antibody for CD68. Formaldehyde-fixed and paraffin-embedded materials of some samples were subjected to scanning electron microscopic examination. Thick sections were cut at 5.0 mm thin for X-ray analysis. The sections were mounted on the celldisk (Sumitomo Bakelite Co., Akita, Japan) and coated with platinum (Pt). The specimens were examined in a S-3400N (HITACHI, Tokyo, Japan) electron microscope operating at 15 kV. Specimens were analyzed in a S-3400N electron microscope fitted with EMAX X-act (HORIBA, Fukuoka, Japan). Analyses processed for 200 s live time at 15 kV accelerating voltage.
For the cases treated with LaC, we investigated the clinical backgrounds and pathological features in both groups with and without the specific histiocytic aggregation. The clinical data examined were age, sex, the original diseases of end-stage renal disease (ESRD), duration of dialysis, LaC administration dose and period. The clinical data also contained the endoscopic findings and macroscopic diagnoses, which were checked again by two endoscopists. Additionally, we investigated the existence of intestinal metaplasia, the existence of Helicobacter pylori, the type of inflammation, and the existence of malignancy.
The data were analyzed using logistic regression analysis at 95% confidence interval (CI) to clarify the respective relations of the daily dose, exposure, and total dose of LaC, with La deposition.
RESULTS
The number of upper gastrointestinal endoscopic examinations was 138 in 112 dialysis patients, and 30 patients were treated with LaC. Histiocytic aggregations were found in the lamina propria mucosae of 15 gastric and one duodenal mucosa (case 14) from 16 patients and not from 14 patients. Both groups with histiocytic aggregations (Group A) and without lesions (Group B) are shown in Table 1 . No histiocytic lesions were observed in the 82 patients without La carbonate administration. In Group A, the HE staining showed aggregations of large histiocytes (Fig. 1a,b ), which were proven by immunohistochemical staining for CD68 (Fig. 1c) . These histiocytes had one or several nuclei and cytoplasm was dark pink to brown. There were amorphous crystalloids within and around the histiocytes, and contained no caseous necrosis. The crystalloids did not show significant positivity for Prussian blue or Kossa staining. No amyloid was determined by DFS staining. The materials which form spiral structures and uneven structures with wrinkles and cracks (Fig. 1d) existed with or within the histiocytes and also by themselves.
Five cases in Group A had endoscopic examinations performed several times (cases 5, 6, 9, 13, 14) . In one of the five cases (case 6) histiocytic aggregations were not detected upon later examination even though they had continued taking LaC.
The results of scanning electron microscopic examination and X-ray analysis showed several peaks of lanthanum (La), phosphorus (P) and platinum (Pt) corresponding with the granulative area from the gastric mucosa of case 9 ( Fig. 2a-c) and duodenal mucosa of case 14. For case 14, we also analyzed the distribution of elements in the duodenal specimens with just a few histiocytes, which had been sampled one year before, of the duodenal mucosa with histiocyte aggregation. For the duodenum, although there were no crystalloid materials, X-ray analysis showed several peaks of lanthanum in both the year-old and present samples (data not shown). The area without any leukocyte infiltration did not contain La (Fig. 2d) .
The lesions appeared even after 4 months' treatment of LaC (totaling 180 g). In contrast, the longest history of LaC treatment was almost 5 years (totaling more than 1300 g) in Group B. The LaC doses in total were 180 g to 1838 g in Group A, and 150 g to 1328 g in Group B. However multiple logistic regression revealed that La deposition had significant correlations to the daily dose of LaC and the total dose of LaC, but not to the administration period of LaC (Table 2) .
Clinical backgrounds were not specific. In both groups, the most frequent causes of ESRD were mainly chronic glomerulonephritis, the specifics of which were not specified. Each group contains four cases of type 2 diabetes mellitus. Gastric cancer existed in three cases of Group B (cases 21, 22, 29: early cancer, case 22: advanced cancer, case 21, 29), but there were no cases of gastric cancer in Group A. Although the dialysis period showed no significant difference between groups A and B, the average of the periods were 115 months and 77 months respectively.
The endoscopic and pathologic findings of La deposition cases are also various in both the former reported cases and ours (Table 3 ). The existence of intestinal metaplasia, erosion and chronic gastritis were relatively common, but H. pylori was observed only three of the 16 cases.
DISCUSSION
For ESRD patients it is important to keep the blood concentration of phosphoric acid in serum, because hyperphosphatemia Figure 1 Histologic features of case 9 (Fig. 1a-c) , which was used for X-ray analysis, and case 1 (Fig. 1d) significantly increases cardiovascular disease and mortality.
14 The "COSMOS study", a large-scale survey of dialysis patients, revealed that 70.5 % of dialysis patients had hyperphosphatemia. 15 Therefore, many types of oral phosphate binders have been developed, such as aluminum hydroxide, calcium carbonate, calcium acetate, nonabsorbable polymers (sevelamer, bixalomer), ferric citrate hydrate and LaC. However, aluminum hydroxide is now considered incompatible for ESRD patients after 20 years' usage, due to it having caused encephalopathy and osteodystrophy, 16 while calcium based phosphate binders increase the risk of vascular calcifications. 17, 18 The side effects of LaC, which have been reported relatively less often than the preceding medicines, are nausea, vomiting and epigastric distress, and are reduced by decreasing the dosage. The histological findings suggest that the multinucleated giant cells appeared as a reaction to the crystalloid materials which have unique structures. Although the intestinal absorption of La is lower than that of aluminum, 4 several cases of La deposition including ours have been confirmed by energy dispersive X-ray spectroscopy, 1,2,7,9,11,13 inductively coupled plasma mass spectrometry 5 and ultrastructural examination. 8, 10 In the former case reports several hypotheses of the mechanism of La deposition were proposed as follows: 2 including ours, and the large intestine. 9 Therefore, the hypothesis based on acidic environment alone has limitations for being the La deposition mechanism in the total tract. (ii) The liver is the main organ which excretes the small absorbed La fraction. From this point hepatic dysfunction should also be watched, although our cases showed no severe liver dysfunction. (iii) In chronic kidney disease (CKD), intercellular junctions in the intestine can be disrupted. Vaziri et al. pointed out that in general the disruption of the gastrointestinal epithelium advances permeability for substances in patients with CKD. 20 The longer dialysis period of the La deposition formation group in our cases (Group A) suggests the involvement of disrupted intercellular junctions throughout the gastrointestinal tract. In addition mucosal barrier defects are reported in gastric intestinal metaplasia. 21 There seemed to be a relevance between La deposition and mucosal barrier defects like intestinal metaplasia, or the many erosions in our cases and in other reports. 2, 9, 13 In the literature there is a case treated with sevelamer, a non-absorbable polymer, which showed crystals in the gastrointestinal tract. 22 This fact means not only La but also other phosphate binders can make depositions. We are afraid that such non-malignant lesions might be diagnosed as merely benign lesions caused by foreign body reactions. So far, no critical symptoms due to LaC have been reported. Intestinal perforation, which the drug manufacturer warns of as one of the serious side effects, is reported in very early stage of LaC administration. We also experienced a case with perforation in a patient treated briefly with LaC, and the perforation site did not show any histological change to suggest La deposition. However, it is important to make differential diagnoses for cases of benign lesions to avoid deterioration. This is because the phosphate binders are indispensable medicines for dialysis patients with hyperphosphatemia, and dialysis patients must take the medicine over a long period. Many patients are treated by several types of phosphate binders at the same time or sequentially, so it is important to follow the patients who are treated with these medicines, including histologic changes of the alimentary tract. Especially in Japan, a society with a high percentage of elderly people, the opportunity for gastrointestinal screening in patients with dialysis is increasing.
In conclusion, we discovered that the daily dose and total dose of LaC show significant correlations to La deposition in the gastrointestinal mucosa. This has not yet been shown statistically in previous reports. To avoid formation of La deposition, reduction of the daily LaC dose might be effective.
